Home

Person

Christian Hartinger

This person is no longer with EPFL

About
Privacy
Disclaimer

Graph Chatbot

Related publications (53)

Synthesis and characterisation of the water soluble bis-phosphine complex [Ru(η6-cymene)(PPh2(o-C6H4O)-κ2-P,O)(pta)]+ and an investigation of its cytotoxic effects

Rosario Scopelliti, Paul Joseph Dyson, Anna Katherine Renfrew, Christian Hartinger

Metal complexes bearing phosphine ligands are attracting increasing attention for their applications in medicinal chem. In particular, organometallic ruthenium-phosphine complexes have been found to exhibit promising antitumor activity. The synthesis, anti ...

Elsevier2010

Nitrile-functionalized pyrrolidinium ionic liquids as solvents for cross-coupling reactions involving in situ generated nanoparticle catalyst reservoirs

Rosario Scopelliti, Paul Joseph Dyson, Zhaofu Fei, Ilaria Biondi, Cinzia Chiappe, Christian Hartinger, Yugang Cui, Manish Chaubey, Yuehui Li, Xuemei Yang

Nitrile-functionalized pyrrolidinium-based ionic liqs. were prepd. and characterized by spectroscopic methods and x-ray crystallog. The application of these new ionic liqs. as reaction media for Suzuki and Stille C-C cross-coupling reactions was studied an ...

Royal Society of Chemistry2010

Osmium(II)-versus ruthenium(II)-arene carbohydrate-based anticancer compounds: similarities and differences

Paul Joseph Dyson, Christian Hartinger, Alexey Nazarov, Muhammad Hanif

The synthesis and in vitro anticancer activity of OsII-arene complexes with carbohydrate-derived phosphite co-ligands are reported. The compds. were characterized by std. methods and the mol. structure of dichlorido(η6-p-cymene)(3,5,6-bicyclophosphite-1,2- ...

Royal Society of Chemistry2010

Maltol-Derived Ruthenium-Cymene Complexes with Tumor Inhibiting Properties: The Impact of Ligand-Metal Bond Stability on Anticancer Activity In Vitro

Christian Hartinger, Alexey Nazarov

Organometallic rutheniumarene compounds bearing a maltol ligand have been shown to be nearly inactive in in vitro anticancer assays, presumably due to the formation of dimeric Ru-II species in aqueous solutions. In an attempt to stabilize such complexes, [ ...

2009

Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta

Paul Joseph Dyson, Andrew Douglas Phillips, Anna Katherine Renfrew, Christian Hartinger, Alexey Nazarov

[M(η6-arene)(ptn)Cl]X (M = Ru, Os; arene = p-cymene, benzene, toluene, hexamethylbenzene; ptn = 3,7-dimethyl-7-phospha-1,3,5-triazabicyclo[3.3.1]nonane; X = Cl-, BF4-) were prepd. and characterized spectroscopically. X-ray diffraction was addnl. used to ch ...

2009

Bioorganometallic chemistry-from teaching paradigms to medicinal applications

Paul Joseph Dyson, Christian Hartinger

In undergraduate level organometallic chem. courses students are usually taught that organometallic compds. are toxic and unstable in air and water. While this is true of many complexes, some are also non-toxic and stable in air and water. Indeed, bioorgan ...

Royal Society of Chemistry2009

Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety

Paul Joseph Dyson, Christian Hartinger, Alexey Nazarov

Aldol reaction of allomaltol with arom. aldehydes, e.g., RC6H4CHO, R = H, 4-NO2, 4-F, 2-F and 3,4,5-(MeO)3C5H2CHO, gave 2-(hydroxyphenylmethyl)-3-hydroxy-6-methylpyran-4(1)-ones, maltol-derived ligands. Organometallic Ru(II)-arene complexes, [RuCl2(cymene) ...

2009

Design of ruthenium-based small molecules as potential therapeutic agents

Paul Joseph Dyson, Christian Hartinger, Alexey Nazarov

This presentation will focus on research carried out in our labs. on organometallic compds. based on the ruthenium(II)-arene unit that exhibit promising in vitro and in vivo anticancer activity and potentially overcome the limitations of platinum based ant ...

2009

From Pyrone to Thiopyrone Ligands-Rendering Maltol-Derived Ruthenium(II)-Arene Complexes That Are Anticancer Active in Vitro

Christian Hartinger, Alexey Nazarov

Ru(II)-arene complexes with pyrone-derived ligands are rendered active against cancer cells by replacement of the coordinated O,O donor with an S,O donor. The different stabilities of these systems may explain the observed influence of the donor atoms on t ...

2009

Influence of the Arene Ligand, the Number and Type of Metal Centers, and the Leaving Group on the in Vitro Antitumor Activity of Polynuclear Organometallic Compounds

Kay Severin, Christian Hartinger, Alexey Nazarov

Dinuclear ruthenium complexes were shown to exhibit strong antiproliferative properties in human tumor cell lines. In order to extend the structure−activity relationships (SARs), a series of new RuII(arene)X complexes (X = Cl, Br, I) linked by pyridinone-b ...

2009

Transferring the Concept of Multinuclearity to Ruthenium Complexes for Improvement of Anticancer Activity

Kay Severin, Christian Hartinger, Alexey Nazarov, Michael Groessl

Multinuclear platinum anticancer complexes are a proven option to overcome resistance of established anticancer compounds. Transferring this concept to ruthenium complexes led to the synthesis of dinuclear Ru(II)-arene compounds containing a bis(pyridinone ...

2009

Gold(III) compounds as anticancer agents: Relevance of gold-protein interactions for their mechanism of action

Paul Joseph Dyson, Christian Hartinger, Angela Casini

Gold(III) compds. constitute an emerging class of biol. active substances, of special interest as potential anticancer agents. During the past decade a no. of structurally diverse gold(III) complexes were reported to be acceptably stable under physiol.-lik ...

2008

Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: A novel approach for the analysis of anticancer metallodrugs in human serum and plasma

Christian Hartinger, Michael Groessl

The development of metal-based chemotherapeutics lacks methods which are capable of providing early indication on the potential of new metal complexes as future anticancer drugs. Since most of these compounds are administered intravenously, serum proteins ...

2008

Carbohydrate-metal complexes and their potential as anticancer agents

Paul Joseph Dyson, Christian Hartinger, Alexey Nazarov

A review. Platinum complex-based chemotherapy is one of the major treatment options of many malignancies. Although severe side effects occur, and only a limited spectrum of tumors can be cured, Pt compds. are used in every second therapy scheme. Thus, many ...

2008

High Resolution Mass Spectrometry for Studying the Interactions of Cisplatin with Oligonucleotides

Hisham Ben Hamidane, Paul Joseph Dyson, Yury Tsybin, Christian Hartinger

Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS) has been used to probe the interaction of the anticancer drug cisplatin with oligonucleotides. The binding kinetics, the nature of the adducts formed, and the location of the binding s ...

2008

Suzuki Coupling Reactions in Ether-Functionalized Ionic Liquids: The Importance of Weakly Interacting Cations

Paul Joseph Dyson, Zhaofu Fei, Andrew Douglas Phillips, Christian Hartinger, Yuehui Li, Xuemei Yang

Imidazolium- and pyridinium-based ionic liqs. with ether/polyether substituents have been evaluated as solvents for palladium-catalyzed Suzuki C-C coupling reactions. In general, reactions proceed more efficiently in these solvents compared to other ionic ...

2008

Emerging Protein Targets for Anticancer Metallodrugs: Inhibition of Thioredoxin Reductase and Cathepsin B by Antitumor Ruthenium(II)-Arene Compounds

Paul Joseph Dyson, Christian Hartinger, Angela Casini

A series of ruthenium(II)-arene (RAPTA) compds. were evaluated for their ability to inhibit thioredoxin reductase (either cytosolic or mitochondrial) and cathepsin B, two possible targets for anticancer metallodrugs. In general, inhibition of the thioredox ...

2008

Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds

Rosario Scopelliti, Paul Joseph Dyson, Antoine Dorcier, Christian Hartinger

The reactions of arene-metal complexes (arene = p-cymene, benzene or pentamethylcyclopentadienyl, metal = Ru, Rh or Os), including 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decanephosphine (pta) and chloro co-ligands, with 9-methylguanine, adenine, and a ser ...

2008

The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways

Paul Joseph Dyson, Christian Hartinger

An investigation of the mol. mechanism of the anticancer activity demonstrated by the ruthenium(II)-arene compd. [Ru(η6-p-cymene)Cl2(pta)] (pta is 1,3,5-triaza-7-phosphaadamantane), termed "RAPTA-C", in Ehrlich ascites carcinoma (EAC) bearing mice is descr ...

2008

In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands

Paul Joseph Dyson, Christian Hartinger, Alexey Nazarov, Michael Groessl, Olivier Pierre Zava, Muhammad Hanif, Frédéric Schmitt

The synthesis and in vitro anticancer activity of dihalo(η6-p-cymene)(3,5,6-bicyclophosphite-α-D-glucofuranoside)ruthenium(II) complexes are described. The compds. were characterized by NMR spectroscopy and ESI mass spectrometry, and the mol. structures of ...

2008

Page 2 of 3